Femasys Launches FemaSeed Complete Fertility Solution for OB/GYNs at ACOG 2026

Key Takeaways

• Femasys Inc. commercially launched FemaSeed Complete, a comprehensive fertility solution enabling OB/GYNs to perform first-line insemination in their own practices
• The solution addresses fertility treatment needs for an estimated 10 million women experiencing infertility in the United States
• Launch occurred at the American College of Obstetricians and Gynecologists (ACOG) 2026 conference in Atlanta on April 22, 2026

---

ATLANTA, April 22, 2026 — Femasys Inc. (NASDAQ: FEMY) announced the commercial launch of FemaSeed Complete at the American College of Obstetricians and Gynecologists (ACOG) 2026 conference. The comprehensive fertility solution enables OB/GYNs to perform first-line insemination procedures entirely within their own practices, potentially transforming fertility care accessibility.

Addressing the Fertility Treatment Gap

With an estimated 10 million women in the United States experiencing infertility, FemaSeed Complete aims to make fertility treatments more accessible and cost-effective. The biomedical innovation company focuses on advancing both fertility solutions and non-surgical permanent birth control options for women worldwide.

IntelligenceRegulatory Impact▾

EMA and MHRA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Market Impact and Clinical Advantages

The launch represents a significant shift in fertility care delivery, allowing OB/GYNs to offer comprehensive fertility services without referring patients to specialized fertility clinics. This integrated approach could reduce treatment costs, eliminate referral delays, and improve patient convenience by keeping care within established physician-patient relationships.

Femasys positions itself as a leading biomedical innovator in women’s reproductive health, with FemaSeed Complete representing the company’s commitment to making fertility treatments more accessible to the millions of women facing infertility challenges.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Industry Reception and Future Outlook

The ACOG 2026 conference launch provides Femasys with direct access to thousands of OB/GYN practitioners who could potentially integrate FemaSeed Complete into their practices. This strategic timing allows the company to demonstrate the solution’s clinical benefits and practice integration advantages to key decision-makers in women’s healthcare.

The fertility treatment market continues expanding as more women seek accessible, cost-effective solutions for infertility. FemaSeed Complete’s practice-based approach could capture significant market share by simplifying the treatment pathway for both physicians and patients.

---

Frequently Asked Questions

What does FemaSeed Complete mean for infertility patients?

FemaSeed Complete allows patients to receive first-line fertility insemination treatments directly from their OB/GYN, eliminating the need for specialty clinic referrals and potentially reducing costs and treatment delays.

When will FemaSeed Complete be available to OB/GYN practices?

Femasys announced the commercial launch at ACOG 2026 on April 22, 2026, indicating the solution is now available for OB/GYN practices to implement.

How does FemaSeed Complete compare to traditional fertility treatments?

Unlike traditional fertility treatments requiring specialized clinic visits, FemaSeed Complete enables OB/GYNs to perform first-line insemination in their own practices, offering greater convenience and potentially lower costs for patients.

Related coverage

• KRX IR Reference : Executive Summary Plan for SCD NDR (ENG, Jun 2026)
• EMEA 2026 Life Sciences Report: Key Market Shifts for Pharma BD and Investors
• Maersk Europe Market Update June 2026: Key Changes for Pharma Supply Chains